Figure 1 MD-BHP Nunavik Alliance Ni-Cu-Co MONTREAL, June 03, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of an important copper-nickel exploration program in Nunavik, following exploration work from 2020 to 2024, during which new Cu-Ni-Co mineralized showings were discovered. This new program will be carried out within the framework of the strategic alliance (the “Alliance”), signed in August 2020 between Midland’s wholly owned subsidiary, ...

Pediatrix Medical Group, Inc. (MD) is strategically positioned to grow on the back of delivering high-quality, evidence-based care in the healthcare space. The company has gained 5.6% in the year-to-date (YTD) period, outperforming the industry average of a 6.4% fall.Pediatrix Medical — with a market cap of $1.2 billion — is a physician services provider company headquartered in Sunrise, FL. It provides newborn, maternal-fetal, radiology, pediatric cardiology and other pediatric subspecialties physician ser ...

Pediatrix Medical Group (MD) closed the last trading session at $13.56, gaining 10.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $17.14 indicates a 26.4% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $2.61. While the lowest estimate of $14 indicates a 3.2% increase from the current price level, the most optimistic anal ...

MONTREAL, May 20, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of an exploration program for gold on its Caniapisc Au project, and also present results from the 2024 till survey, in the Eeyou Istchee James Bay and Canispiscau regions. The Caniapisc Au project is wholly owned by Midland and consists of 94 claims covering an area of 47 square kilometres. Highlights: Initiation of the June exploration program, including prospecting and a soil sampli ...

Shares of Pediatrix Medical Group, Inc. (MD) have risen 11.5% since it reported first-quarter 2025 results on May 6. The quarterly results benefited from strong same-unit revenue growth, improved payor mix and growth in hospital contract administrative fees. A decline in the overall expense level also contributed to the upside. However, the upside was partly offset by higher same-unit clinical compensation costs.Pediatrix Medical reported first-quarter 2025 adjusted earnings per share (EPS) of 33 cents, whi ...

Pediatrix Medical Group (MD) Q1 2025 Earnings Call May 06, 2025 09:00 AM ET Company Participants Mark Ordan - CEO & Chair of the Board of DirectorsKasandra Rossi - EVP, CFO & TreasurerA.J. Rice - Managing DirectorJack Slevin - VP - Healthcare Services Equity Research Conference Call Participants Pito Chickering - Analyst Operator Certain statements and information during this conference call may be deemed to be forward looking statements within the meaning of the Federal Private Securities Litigation Reform ...

Pediatrix Medical Group (MD) Q1 2025 Earnings Call May 06, 2025 09:00 AM ET Speaker0 Certain statements and information during this conference call may be deemed to be forward looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward looking statements are based on assumptions and assessments made by Pediatrics' management in light of their experience and assessment of historical trends, current conditions, expected future developments, and other fa ...

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this physician group would post earnings of $0.37 per share when it actually produced earnings of $0.51, delivering a surprise of 37.84%.Over the last four quarters, t ...

Financial Performance - Net revenue for the three months ended March 31, 2025, was $458.4 million, a decrease of $36.7 million, or 7.4%, compared to $495.1 million for the same period in 2024[73] - Same-unit net revenue increased by $26.1 million, or 6.2%, driven by a $19.4 million increase from net reimbursement-related factors and a $6.7 million increase related to patient service volumes[73] - Adjusted EBITDA for the three months ended March 31, 2025, was $49.2 million, compared to $37.2 million for the same period in 2024, reflecting an increase of $11.9 million[72] - Adjusted EPS for the three months ended March 31, 2025, was $0.33, compared to $0.20 for the same period in 2024, representing a 65% increase[72] - Income from operations increased by $16.2 million, or 102.0%, to $32.1 million for the three months ended March 31, 2025, compared to $15.9 million for the same period in 2024[79] - Operating margin improved to 8.4% for the three months ended March 31, 2025, up from 4.9% for the same period in 2024[80] - Net income rose to $20.7 million for the three months ended March 31, 2025, compared to $4.0 million for the same period in 2024[83] - Adjusted EBITDA increased to $49.2 million for the three months ended March 31, 2025, from $37.2 million for the same period in 2024[83] Expenses - Practice salaries and benefits decreased by $32.1 million, or 8.7%, to $337.0 million for the three months ended March 31, 2025, compared to $369.1 million for the same period in 2024[74] - General and administrative expenses were $58.6 million for the three months ended March 31, 2025, a decrease of $1.6 million compared to $60.2 million for the same period in 2024[76] - Transformational and restructuring related expenses were $6.6 million for the three months ended March 31, 2025, compared to $8.5 million for the same period in 2024[78] - Total non-operating expenses decreased to $4.0 million for the three months ended March 31, 2025, from $8.1 million for the same period in 2024[81] Cash Flow and Liquidity - Cash used in operating activities decreased to $116.1 million for the three months ended March 31, 2025, from $122.6 million for the same period in 2024[87] - As of March 31, 2025, the company had $99.0 million in cash and cash equivalents, down from $229.9 million at December 31, 2024[85] - The outstanding principal balance on the Amended Credit Agreement was $210.9 million as of March 31, 2025[96] - A 1% change in interest rates would impact income before taxes by approximately $2.1 million per year based on the outstanding balance of the Amended Credit Agreement[104] Operational Metrics - The percentage of patient service revenue reimbursed under government-sponsored healthcare programs decreased during the three months ended March 31, 2025, compared to the same period in 2024[61] - Days sales outstanding (DSO) improved to 47.6 days at March 31, 2025, down from 52.2 days at March 31, 2024[89] Strategic Changes - The company completed the exit of its pediatric office-based practices as of December 31, 2024, to focus on hospital-based and maternal-fetal medicine services[62] - The company anticipates potential impacts from changes in government-sponsored healthcare programs and the expiration of COVID-19 related emergency declarations[67]

• Net revenue of $458 million; • Net income of $21 million; and • Adjusted EBITDA of $49 million. Operating Results– Three Months Ended March 31, 2025 Pediatrix's net revenue for the three months ended March 31, 2025 was $458.4 million, compared to $495.1 million for the prior-year period. This decrease reflects the impact of non-same unit activity, primarily practice dispositions, partially offset by growth in same-unit net revenue of 6.2 percent. FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice Pres ...